Barclays analyst Benjamin Budish lowered the firm’s price target on KKR (KKR) to $129 from $181 and keeps an Overweight rating on the shares as part of a Q1 earnings preview. The firm still “very much” likes the long-term story, but says that given recent market volatility it revised down fiscal 2025 capital markets fees and realizations for KKR.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KKR:
- M&A News: KKR Gets Green Light for $2B Takeover of British Healthcare Firm but Stock Remains in Doldrums
- KKR price target lowered to $126 from $183 at TD Cowen
- EQT to sell Karo Healthcare to KKR, terms undisclosed
- EQT Corporation to sell Karo Healthcare to KKR, terms undisclosed
- KKR close to deal to acquire Karo for over $2.7B, Bloomberg reports